Acalabrutinib Plus BR Leads to High CR Rates in Treatment-Naive, Relapsed/Refractory MCL
June 9th 2023The addition of acalabrutinib to bendamustine and rituximab demonstrated potent and durable responses despite a high incidence of grade 3/4 adverse effects in patients with previously untreated and relapsed/refractory mantle cell lymphoma.
Daratumumab Plus Ixazomib and Dexamethasone Produces Significant Responses in R/R Multiple Myeloma
June 9th 2023The combination of daratumumab, ixazomib, and dexamethasone produced rapid and encouraging responses rates following lenalidomide–based therapy in patients with relapsed/refractory multiple myeloma, according to findings from the final analysis of the phase 2 DARIA trial.
Ibrutinib Plus Venetoclax Produces High MRD Negativity Rate in Previously Untreated CLL
The addition of venetoclax to ibrutinib resulted in a high rate of minimal residual disease negativity in the blood and marrow of patients with previously untreated chronic lymphocytic leukemia.
Zanubrutinib Improves QOL Outcomes Vs Bendamustine/Rituximab in CLL/SLL
Zanubrutinib achieved favorable health-related quality of life outcomes compared with bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.
REGN5458 Elicits Early, Sustainable Responses in Heavily Pretreated Multiple Myeloma
June 13th 2022The bispecific antibody REGN5458 elicited rapid responses that were further characterized by their depth, durability, and low incidence of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.
Venetoclax Plus Obinutuzumab Confers Long-Term Survival Benefits in Unfit Patients With CLL
Venetoclax plus obinutuzumab remains an effective fixed-duration treatment option for patients with chronic lymphocytic leukemia and coexisting conditions, according to updated efficacy and safety data from the ongoing phase 3 CLL14 trial.
Ropeginterferon Alfa-2b Demonstrates Long-Term QOL Improvements in Polycythemia Vera
Treatment with ropeginterferon alfa-2b-njft induced low symptom burden and low phlebotomy requirement compared with best available treatment in patients with polycythemia vera, according to long-term data from the phase 3 PROUD-PV and CONTINUATION-PV trials.
Tisagenlecleucel Maintains Durable Response at 5 Years in Pediatric/Young Adult Patients With B-ALL
June 13th 2022Long-term follow-up from the phase 2 ELIANA trial, showed that tisagenlecleucel continued to demonstrate durable efficacy in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Bezuclastinib Demonstrates Early Promise in Advanced Systemic Mastocytosis
Bezuclastinib showcased early signs of clinical activity in that it resulted in a meaningful reduction in serum tryptase levels, as well as reductions in mast cell burden and KIT D816V variant allele frequency, in adult patients with advanced systemic mastocytosis.
Talquetamab Plus Daratumumab Generates High Response Rate in CD38-Refractory Myeloma
June 12th 2022The combination of talquetamab and daratumumab led to early onset and durable responses that deepened over time in patients with heavily pretreated multiple myeloma, most of whom were anti-CD38 refractory, according to findings from the phase 1b TRIMM-2 study.
Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis
The combination of pelabresib and ruxolitinib produced responses that proved to be durable beyond week 24 in patients with myelofibrosis who experienced a suboptimal response to ruxolitinib and in those who were JAK inhibitor naïve.
Frontline Subcutaneous Epcoritamab Plus R-CHOP Elicits ORR of 100% in High-Risk DLBCL
The combination of epcoritamab and R-CHOP produced high overall response rates and complete metabolic response rates with a manageable toxicity profile in patients with diffuse large B-cell lymphoma.
BRUIN CLL-313 Trial To Evaluate Pirtobrutinib in Untreated CLL/SLL
The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.
Zandelisib Elicits High Response in Relapsed/Refractory Follicular Lymphoma
June 12th 2022Zandelisib, a potent and selective oral PI3Kδ inhibitor, elicited a high overall response rate as a single agent in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to data from the phase 2 TIDAL trial.
Long-term Treatment With Luspatercept Reduces Transfusion Dependence Associated With β-Thalassemia
June 12th 2022The longest duration of reduction in red blood cell transfusion dependence was reported among patients with β-thalassemia who received continued treatment with luspatercept-aamt in the updated data from the phase 3 BELIEVE trial.
Quizartinib Triplet Shows Activity in Heavily Pretreated, FLT3-ITD–Mutated AML
The triplet combination regimen comprised of quizartinib, decitabine, and venetoclax elicited encouraging responses in heavily pretreated patients with relapsed/refractory FLT3-ITD–mutated acute myeloid leukemia who were previously exposed to a FLT3 inhibitor.
Momelotinib Shows Superiority Over Danazol in Symptomatic and Anemic Myelofibrosis
Momelotinib demonstrated significant improvements in symptoms, spleen size, and anemia measures compared with danazol in patients with symptomatic and anemic myelofibrosis who previously received treatment with a JAK inhibitor.
Decitabine Displays Comparable Outcomes, Improved Safety to Induction Chemotherapy in Older AML
June 11th 2022Decitabine demonstrated a comparable overall survival and rate of hematopoietic stem cell transplant in addition to a lower incidence of adverse effects vs induction chemotherapy with daunorubicin and cytarabine in older patients at least 60 years of age with acute myeloid leukemia.
CAR T-Cell Therapy ARI0002H Elicits Encouraging Responses in Relapsed/Refractory Multiple Myeloma
ARI0002H, a BCMA-directed CAR T-cell therapy, achieved promising response rates in patients with relapsed/refractory multiple myeloma, according to findings from a phase 1/2 trial.